STAT3 and cancer: Similarly, EGCG reduced ROS-dependent processes, such as ERK1/2 and STAT1 activation, but not cisplatin-mediated reduction in p-STAT3 in UMSCC 10B cancer cells or the p-STAT3/p-STAT1 ratios (Figure 7c), which averaged 0.29±0.06, 0.44±0.10 and 1.42±0.39 for the cisplatin, EGCG+cisplatin and EGCG- alone groups, respectively.